The Apixaban market, currently a multi-billion-dollar powerhouse, is on the cusp of a revolutionary change. While the branded drug Eliquis has dominated the Novel Oral Anticoagulant (NOAC) segment, its impending patent cliff, anticipated in major markets post-2026, sets the stage for a new competitive landscape. Experts predict that the overall value of the market will continue its strong...